LUXTURNA 5 X 10^12 GENOMURI VECTOR/ml 5 x 10^12 vg/ml concentrate and solvent for solution for injection EUROPHARM ORIGINAL MEDICINE
Chemical substance: voretigene neparvovec
ATC code: S01XA27 • Sensory organs | Other ophthalmologicals
Active substance
Results for the substance voretigene neparvovec
1 result
About this active substance
Voretigene neparvovec is a gene therapy used for the treatment of retinal dystrophy associated with biallelic mutations in the RPE65 gene. This rare condition leads to progressive vision loss and eventual blindness. Voretigene neparvovec uses an adeno-associated viral (AAV) vector to deliver a functional copy of the RPE65 gene to retinal cells, thereby restoring the production of the protein required for the visual cycle.
The medication is administered via subretinal injection performed by a specialized ophthalmic surgeon. The treatment is indicated for patients aged at least one year who have sufficient viable retinal cells.
Common side effects include ocular inflammation, increased intraocular pressure, eye pain, and photophobia. In rare cases, severe complications such as retinal detachment or ocular infections may occur.
Voretigene neparvovec represents a major innovation in the treatment of genetic eye diseases, offering patients a chance to partially regain vision and improve their quality of life.
The medication is administered via subretinal injection performed by a specialized ophthalmic surgeon. The treatment is indicated for patients aged at least one year who have sufficient viable retinal cells.
Common side effects include ocular inflammation, increased intraocular pressure, eye pain, and photophobia. In rare cases, severe complications such as retinal detachment or ocular infections may occur.
Voretigene neparvovec represents a major innovation in the treatment of genetic eye diseases, offering patients a chance to partially regain vision and improve their quality of life.